Global pharma leadership isn't built through exports alone. It's built by scaling businesses across markets, regulations, and cultures.
Mahidhwaj Sisodia has been appointed Chief Business Officer, International Business at USV PRIVATE LIMITED, after a 29 year career building pharmaceutical businesses across 90 plus countries.
His journey spans Sandu Pharmaceuticals Ltd. , Alkem Laboratories Ltd., Tablets (India) Ltd , Tagros chemicals india (p) ltd , JB Chemicals & Pharmaceuticals, Cadila Pharmaceuticals Limited, and now USV PRIVATE LIMITED. Along the way, he has led international business across Asia, Europe, Africa, and Latin America, progressing from export operations to enterprise leadership.
Since joining USV in 2022, he has driven global FDF and API businesses across 65 plus countries, leading B2B and B2C growth, strategic partnerships, market expansion, and cross functional teams. As Chief Business Officer, he now oversees USV's entire international business and overseas subsidiaries.
His career highlights what today's pharma leaders need, global market access, licensing, strategic alliances, commercial leadership, and the ability to scale businesses across complex international markets.
At Boardroom CXO, we're seeing pharmaceutical companies increasingly appoint leaders with proven global execution, multi continent experience, and business development expertise to lead international growth.
Question for pharma leaders: What's the tougher challenge today, expanding in regulated markets, or scaling growth across emerging markets with evolving commercial and distribution ecosystems?
First published on the Boardroom CXO LinkedIn page on 30 July 2026. To correct or remove it, write to [email protected].
Boardroom CXO runs executive search for CXO and senior leadership roles in India and the UAE. Talk to us about a leadership hire.
